Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00743834
Recruitment Status : Unknown
Verified September 2008 by Rogers Center for Research & Training, Inc..
Recruitment status was:  Not yet recruiting
First Posted : August 29, 2008
Last Update Posted : September 4, 2008
Information provided by:
Rogers Center for Research & Training, Inc.

Brief Summary:
This study will test the hypotheses that: 1. 12 weeks of Luvox-CR plus web-based Cognitive-Behavioral Therapy (CBT) [CT-STEPS] will produce greater symptom relief of OCD than treatment with Luvox-CR alone; and, 2. subjects receiving 12 weeks of CT-STEPS added to Luvox-CR treatment after 12-weeks of Luvox-CR monotherapy will experience greater OCD symptom relief (from weeks 12-24) than those continuing Luvox-CR treatment and having access to CT-STEPS from week one. 3. subjects who begin CT-STEPS at week 12 will be more likely to complete it than those who begin CT-STEPS at baseline.

Condition or disease Intervention/treatment Phase
Obsessive Compulsive Disorder Drug: Luvox CR Behavioral: Behavioral Therapy Phase 4

Detailed Description:

Primary Endpoint(s): Change in Y-BOCS score from baseline to endpoint at weeks 12 and 24; and, number (and percent) "responders" at weeks 12 and 24, defined as subjects with a 35% decrease in Y-BOCS score at endpoint and a Clinical Global Impressions score of 1 or 2 (very much or much improved).

Secondary Endpoint(s):

  1. change in scores on the Work and Social Adjustment Scale, a quality of life measure
  2. change in scores on the Work Productivity and Activity Impairment


    Specific Health Problem scale; in particular, we will analyze change in work hours/week lost because of OCD, and change in effect of OCD on work productivity (0-10 scale).

  3. dollar cost per responder
  4. dollar cost per total number of patients needed to produce one additional responder in the Luvox-CR plus web-based CBT group over the number produced by Luvox-CR alone, i.e., dollar cost per number needed to treat
  5. dollar cost per 5% decrease in Y-BOCS score at weeks 12 and 24 in the two treatment groups.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Cost-Effectiveness of Adding Web-Based CBT to Luvox CR for OCD
Study Start Date : September 2008
Estimated Primary Completion Date : August 2009
Estimated Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Effectiveness of Luvox CR plus Web-based CBT for OCD
Drug: Luvox CR
In light of the Luvox-CR dosing procedure of Hollander et al (2003) (50 mg increments weekly) and the available dose capsules of Luvox-CR (100 mg and 150 mg), the Luvox-CR dose will be increased over the first 6 weeks of treatment as tolerated in 50 mg to 100-mg increments every week, as tolerated and clinically indicated, to a bedtime dose between 100 and 300 mg/day. The dose will then be held constant for the duration of the study

Behavioral: Behavioral Therapy
The web-based CBT (CT STEPS) includes an introductory session explaining the treatment, with videotapes of OCD patients who used an earlier version, along with 9 subsequent treatment modules. The CBT will include weekly email feedback from a psychologist in response to questions asked about the CBT by the subjects assigned to this treatment arm.

Primary Outcome Measures :
  1. The primary outcome measure (Y-BOCS score) will be obtained by clinician rating [ Time Frame: screening, baseline, and end of weeks 4, 8, 12, 16, 20 and 24. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Men and women aged 18 years, with OCD of at least 1 year's duration, meeting DSM-IV diagnostic criteria, and having a baseline Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score of 18.

Exclusion Criteria:

  • Pregnant or nursing women or women of childbearing age not using an effective contraceptive method
  • Organic mental disorder
  • Bipolar disorder
  • Psychotic disorder
  • History of substance abuse or dependence within 3 years of evaluation for study
  • Major depression with suicidal risk
  • Major depression dominating the clinical picture
  • Panic disorder
  • Personality disorder severe enough to interfere with cooperation with study procedures
  • Need for antipsychotic medication
  • Depot neuroleptic drug within 6 months
  • Fluoxetine within 5 weeks
  • An MAOI within 2 weeks, any nightly sedative, or taking a medication that may interact with fluvoxamine
  • Serious or unstable medical condition (hematological, endocrine, cardiovascular, renal or gastrointestinal), a history of malignancy (other than excised basal cell carcinoma), history of brain disease, including more than one childhood febrile convulsion and all forms of epilepsy; or, are receiving behavior therapy for OCD.
  • Subjects who qualify for the study while taking an SSRI must have been taking their current dose or a higher dose for at least 12 weeks prior to study baseline.
  • Subjects who qualify for the study while taking fluvoxamine must be taking no more than 150 mg/day and never had a trial at a higher dose, must be believed by the investigator to be able to tolerate an increase to 250 mg/day starting at baseline, and must have been taking their pre-study dose or a higher dose (up to 150 mg/day) for at least 12 weeks prior to study baseline.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00743834

Layout table for location contacts
Contact: Amy Perkins, BA 414-328-3702

Layout table for location information
United States, Wisconsin
The Rogers Center for Research & Training, Inc.
Milwaukee, Wisconsin, United States, 53227-1133
Contact: Amy Perkins, BA    414-328-3702   
Contact: Alex Bruss, BS    414-328-3710   
Principal Investigator: John H Greist, MD         
Sponsors and Collaborators
Rogers Center for Research & Training, Inc.
Layout table for investigator information
Principal Investigator: John H Greist, MD The Rogers Center for Research & Training, Inc.
Layout table for additonal information
Responsible Party: John H Greist, MD, Rogers Center for Research & Training, Inc. Identifier: NCT00743834    
Other Study ID Numbers: JIIT-07-LCR001a
First Posted: August 29, 2008    Key Record Dates
Last Update Posted: September 4, 2008
Last Verified: September 2008
Additional relevant MeSH terms:
Layout table for MeSH terms
Compulsive Personality Disorder
Obsessive-Compulsive Disorder
Personality Disorders
Mental Disorders
Anxiety Disorders
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Antidepressive Agents, Second-Generation
Antidepressive Agents
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Cytochrome P-450 CYP2C19 Inhibitors